{"id":"W4220931859","doi":"10.1007/s10549-021-06417-y","title":"Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)","year":2022,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Hôpital du Saint-Sacrement; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Epirubicin; Medicine; Breast cancer; Internal medicine; Placebo; Cyclophosphamide; Clinical endpoint; Chemotherapy; Oncology; Cancer; Surgery; Clinical trial; Gastroenterology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001145408,0.00028724,0.001255176,0.0004173296,0.0002780905,0.00001940745,0.000232903,0.00006452383,0.0001646414],"category_scores_gemma":[0.00006996888,0.000184934,0.0001161292,0.000789358,0.0006262469,0.00008367257,0.0001788056,0.0003624913,7.912394e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001941271,"about_ca_system_score_gemma":0.002898637,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.09322605,"about_ca_topic_score_gemma":0.00893788,"domain_scores_codex":[0.9964893,0.0007236467,0.0007348137,0.0005134211,0.0008662668,0.0006725901],"domain_scores_gemma":[0.9977963,0.0008224432,0.0003207366,0.0004325698,0.0003747032,0.0002532283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8675064,0.004516812,0.001838621,0.00007364594,0.0006921391,0.0001102777,0.008595607,0.0003392293,0.0008528459,0.00001703723,0.0001609451,0.1152965],"study_design_scores_gemma":[0.8159369,0.04326845,0.1104896,0.001026818,0.0002590096,0.0002923862,0.02103903,0.0001459343,0.005657969,0.00003534132,0.00156203,0.000286519],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891154,0.001424654,8.445798e-7,0.003149001,0.00008353102,0.003500592,0.00224953,0.00001055231,0.0004658709],"genre_scores_gemma":[0.9933416,0.002247775,0.00003330851,0.00004073937,0.0002190895,0.003858997,0.00002067694,0.00003118221,0.0002065996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1150099,"threshold_uncertainty_score":0.9128122,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.086597028550857,"score_gpt":0.3949531656894934,"score_spread":0.3083561371386364,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}